Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
7,8-Diaminopelargonic acid synthase (DAPA synthase; EC 2.6.1.62/2.6.1.105), commonly referred to as 7,8-diaminononanoate synthase in functional nomenclature, is a pyridoxal phosphate-dependent aminotransferase that catalyzes the transfer of an amino group from S-adenosyl-L-methionine (SAM) or L-lysine to 7-keto-8-aminopelargonic acid (KAPA), producing 7,8-diaminononanoate (DAPA) in the third-to-last step of de novo biotin biosynthesis. This process is essential for microbial viability and is absent in animals, making the enzyme a valuable antimicrobial drug target. DAPA synthase is encoded by the bioA (or occasionally bioK) gene in various bacteria and is part of a tightly regulated biotin operon cluster
Enzyme inhibitors would typically act by blocking the aminotransferase activity, ultimately depleting biotin synthesis in susceptible bacteria or fungi
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 7,8-diaminopelargonic acid synthase (DAPA synthase).